logo
OS Therapies FDA Meeting Request Granted

OS Therapies FDA Meeting Request Granted

Business Wire22-04-2025

NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) ('OS Therapies' or 'the Company'), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that the US Food & Drug Administration ('FDA') granted the Company's meeting request to gain alignment on the surrogate endpoint to support Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma. FDA granted a written response-only meeting and confirmed that its response would be received by mid-June 2025, in time for the Company to present the statistical analysis as part of the keynote presentation closing out major osteosarcoma conference MIB Factor on June 28, 2025 at 3:30pm MDT.
'We are pleased that FDA agreed to the requested meeting forward and work within the timelines of the meeting type requested so that we would be able to share our analysis with the patient and physician communities that will be represented at MIB Factor in late June,' said Robert Petit, Chief Medical & Scientific Officer of OS Therapies.
'We remain on track for an early third quarter submission and are hopeful to receive approval by year-end 2025 in order to bring this life saving treatment to patients in early 2026,' said Paul Romness, CEO of OS Therapies.
OST-HER2 has received Rare Pediatric Disease Designation (RPDD) for osteosarcoma from the US FDA, and if it receives a conditional BLA via Accelerated Review prior to September 30, 2026, it will become eligible to receive a Priority Review Voucher (PRV) that it intends to immediately sell. The most recent PRV sale, valued at $150 million, occurred in February 2025.
The osteosarcoma treatment market was estimated at $1.2 billion in 2022 according to Data Bridge Market Research. Approximately 50% of patients are diagnosed with a lung metastasis at some point following surgical resection and chemotherapy. 3-year survival rates in patients who were not diagnosed with a metastasis are 59%. 3-year survival rates in patients who were diagnosed with pulmonary metastasis were 30%. The Company believes the market opportunity for OST-HER2 in the prevention of lung metastases is over $500 million.
OST-HER2, an immunotherapy for osteosarcoma using a HER2 bioengineered form of the bacteria Listeria monocytogenes to trigger a strong immune response against cancer cells expressing HER2, is being featured in the upcoming movie Shelter Me: The Cancer Pioneers. The movie offers a look into canine comparative oncology, a field that compares treatment of cancers in dogs to those in people and covers developing treatments for rare forms of cancer. A trailer for the movie is available here. The movie will air live nationally on PBS and be available via streaming on PBS' website in early May 2025.
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the US Food & Drug Administration and Fast-Track and Orphan Drug designations from the US FDA and European Medicines Agency. The Company positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the US FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma.
In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the US FDA and grant of a priority review voucher and other risks and uncertainties described in 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in the Company's registration statement on Form S-1 filed with the Securities and Exchange Commission (the 'SEC') on November 12, 2024, as amended on November 27, 2024, and other subsequent documents we file with the SEC, including but not limited to our Quarterly Reports on Form 10-Q. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

GRUPO SIMEC SAB DE CV ANNOUNCES THE PRESENTATION OF DOCUMENT 20F TO THE SEC
GRUPO SIMEC SAB DE CV ANNOUNCES THE PRESENTATION OF DOCUMENT 20F TO THE SEC

Yahoo

time18 minutes ago

  • Yahoo

GRUPO SIMEC SAB DE CV ANNOUNCES THE PRESENTATION OF DOCUMENT 20F TO THE SEC

GUADALAJARA, Mexico, June 11, 2025 /PRNewswire/ -- Grupo Simec, S.A.B. de C.V. (NYSE-MKT: SIM) (the "Company") May 15, 2025 filed its Annual Report on Form 20-F for the year ended December 31, 2024 with the U.S. Securities and Exchange Commission at The Form 20-F is also available on the investor relations section of the Company's website at Shareholders may request a hard copy of the Form 20-F, including the Company's complete audited financial statements for the year ended December 31, 2024, free of charge, by contacting the Company's Finance coordinator, Mario Moreno Cortez, by email at mmoreno@ About Grupo Simec Grupo Simec is a diversified manufacturer, processor and distributor of SBQ steel and structural steel products with production and commercial operations in Mexico and Brazil, and limited commercial operations in the United States. Grupo Simec is also an important producer of structural and light structural steel products in Mexico in terms of sales volume. Grupo Simec's SBQ products are used across a broad range of highly engineered end-user applications, including axles, hubs and crankshafts for automobiles and light trucks, machine tools and off-highway. Contact: Mario Moreno CortezGrupo Simec, S.A.B. de Lázaro Cárdenas 60144440 Guadalajara, Jalisco, México+52 33 3770 6734 View original content: SOURCE Grupo Simec, S.A.B. de C.V.

RFK Jr. names 8 new members of vax advisory panel
RFK Jr. names 8 new members of vax advisory panel

Axios

time27 minutes ago

  • Axios

RFK Jr. names 8 new members of vax advisory panel

HHS Secretary Robert F. Kennedy on Tuesday named eight new members to serve on an influential federal vaccine advisory panel after firing all 17 of the committee's members. Why it matters: While Kennedy posted on X that the new appointees are committed to evidence-based medicine, several have a history of expressing anti-vaccine sentiment or voicing concerns about COVID-19 or mRNA vaccines. Some were also signers of the Great Barrington Declaration, a petition authored by a group of scientists including current NIH Director Jay Bhattacharya that advocated for allowing COVID to spread among young, healthy people to reach herd immunity faster. The approach drew fierce criticism from many experts. The Advisory Committee on Immunization Practices serves as an outside expert source to make recommendations to the Centers for Disease Control. Its recommendations can influence whether insurers cover vaccines. The new members are: Martin Kulldorf, a biostatistician who previously served on the Vaccine Safety Subgroup of ACIP and who was a co-author of the Great Barrington Declaration. He was fired from Harvard University for refusing COVID vaccination. He later claimed it was because he was " too pro-vaccine." Robert Malone, a physician-scientist and biochemist who made early contributions to mRNA vaccine technology. He was dubbed a "misinformation star" by the New York Times for spreading false information about COVID and mRNA shots, including claiming he was an inventor of the technology.. Cody Meissner, a professor of pediatrics at the Geisel School of Medicine at Dartmouth, who has previously held advisory roles for both CDC and FDA. He is also a signer of the Great Barrington Declaration and co-wrote an editorial with FDA Commissioner Marty Makary during the COVID pandemic arguing against masking for children. Retsef Levi, a professor of operations research at MIT. Levi has been a critic of mRNA vaccines, posting on social media in 2023 that "we have to stop giving them immediately." Vicky Pebsworth, a long-time nurse with a Ph.D. in public health. She previously served on the FDA's Vaccine and Related Biological Products Advisory Committee and on the National Vaccine Advisory Committee's vaccine safety working group for the H1N1 vaccine. As of 2022, Pebsworth served on the board of the National Vaccine Information Center, an anti-vaccine group. She's spoken publicly about her son experiencing long-term health issues following vaccines at 15 months old. Joseph Hibbeln, a psychiatrist and neuroscientist who previously worked at the NIH for many years. He primarily studies nutrition and brain health. Michael Ross, a clinical professor of obstetrics and gynecology at George Washington University and Virginia Commonwealth University. James Pagano, an emergency medicine physician licensed in Florida and California. The other side: The announcement immediately stoked fears from some public health experts that the committee selections are overly skeptical of vaccines. "It's entirely possible that some of these people may be completely non-problematic," Angela Rasmussen, a virologist at the Vaccine and Infectious Disease Organization at the University of Saskatchewan. However, others are "unbelievably anti-vax people. They are 100% not going to approach this in good faith."

BuildDirect Retains Market-Making Services
BuildDirect Retains Market-Making Services

Yahoo

time29 minutes ago

  • Yahoo

BuildDirect Retains Market-Making Services

Vancouver, British Columbia--(Newsfile Corp. - June 11, 2025) - Technologies Inc. (TSXV: BILD) ("BuildDirect" or the "Company") a leading omnichannel building material retailer, today announced that the Company, subject to regulatory approval, retained Venture Liquidity Providers Inc. ("VLP") to execute its market-making service to provide assistance in maintaining an orderly trading market for the common shares of the Company. The market-making service will be undertaken by VLP through a registered broker, W.D. Latimer Co. Ltd., in compliance with the applicable policies of the TSX Venture Exchange and other applicable laws. For its services, the Company has agreed to pay VLP CAD$5,000 per month. The agreement may be terminated at any time by the Company or VLP. The Company and VLP act at arm's length, and VLP has no present interest, directly or indirectly, in the Company or its securities. The finances and the shares required for the market-making service are provided by W.D. Latimer. The fee paid by the Company to VLP is for services only. VLP is a specialized consulting firm based in Toronto providing a variety of services focused on TSXV-listed issuers. About BuildDirect BuildDirect (TSXV: BILD) is an expanding omnichannel building materials retailer, specializing in Pro Centers-strategic distribution hubs designed to serve professional contractors and trades. The Company is actively scaling its footprint through a combination of organic growth and strategic acquisitions, driving efficiency and market expansion. For more information, visit Forward-Looking Information: This press release contains statements which constitute "forward-looking statements" and "forward-looking information" within the meaning of applicable securities laws (collectively, "forward-looking statements"), including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking statements are often identified by the words "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" or similar expressions. These statements reflect management's current beliefs and expectations and are based on information currently available to management as at the date hereof. Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. Among those factors are changes in consumer spending, availability of mortgage financing and consumer credit, changes in the housing market, changes in trade policies, tariffs or other applicable laws and regulations both locally and in foreign jurisdictions, availability and cost of goods from suppliers, fuel prices and other energy costs, interest rate and currency fluctuations and changes in general economic, business and political conditions. These forward-looking statements may be affected by risks and uncertainties in the business of the Company and general market conditions. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release reflect the Company's expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. There may be other risks, uncertainties and factors that cause results not to be as anticipated, estimated or intended and such changes could be material. These forward-looking statements are made as of the date of this press release, and BuildDirect assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. For further information: Shawn Wilson, CEOshawnwilson@ BuildDirect Investor Relationsir@ To view the source version of this press release, please visit Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store